TuHURA Biosciences, Inc. (HURA)
TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda; and Delta receptor technology to develop tumor microenvironment modulators in the form of first-in-class bi-functional and bi-specific antibody-drug conjugates targeting Myeloid Derived Suppressor Cells. In addition, the company is also developing Immune Fx; IFx-3.0, an mRNA innate immune agonist candidate for intravenous or autologous whole cell administration for blood-related cancers. The company was formerly known as Morphogenesis, Inc. and changed its name to TuHURA Biosciences, Inc. in December 2023. The company was founded in 1995 and is based in Tampa, Florida. TuHURA Biosciences, Inc. operates as a subsidiary of CohBar, Inc.
- Ticker
- HURA
- Exchange
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Market cap
- $103.80M
- 52-week range
- $0.41 - $3.43
Valuation
- Share price
- $1.63 (close of Nov 6, 2026)
- P/E (TTM)
- -3.02x
- Price to book
- 5.61x
- Price to free cash flow
- -3.47x
- Enterprise value
- $111.99M
- Book value per share
- $0.29
Price performance
| Period | Change |
|---|---|
| 1 day | +1.24% |
| 5 days | -15.54% |
| 1 month | -16.41% |
| 3 months | -23.11% |
| 6 months | -35.83% |
| Year to date | +114.47% |
| 1 year | -33.47% |
| 3 years | -89.17% |
| 5 years | -99.90% |
| 10 years | -100.00% |
| All time | -99.99% |
Short interest
- As of
- Oct 15, 2026
- Short % of float
- 12.05%
- Shares short
- 5.94M
- Days to cover
- 26.86
- Change since prior report
- -2.59%
- Source
- FINRA consolidated short interest
Profitability and growth
- Return on equity
- -143.57%
- Return on invested capital
- -136.03%*
- Return on assets
- -109.87%
- Return on capital employed
- -137.29%*
* Estimated EBIT: pre-tax income + net interest. This company reports no operating income line.
Cash flow and balance sheet
- Free cash flow yield (TTM)
- -28.81%
- Current ratio
- 0.18x
- Net debt to EBITDA
- -0.28x
Latest reported year
- Period end
- Dec 31, 2025
- Fiscal year
- 2025
- EBITDA
- -$29.35M
- Net income
- -$30.05M
- Earnings per share
- $-0.63
- Research and development
- $20.53M
- Interest expense
- $625.28K
- Shares outstanding
- 47.93M
Income statement by year
| Period end | Net income | EPS |
|---|---|---|
| 2025-12-31 | -$30.05M | -$0.63 |
| 2024-12-31 | -$21.68M | -$1.21 |
| 2024-06-30 | -$8.32M | -$11.20 |
| 2023-12-31 | -$29.32M | -$2.47 |
| 2023-06-30 | -$14.65M | -$324.45 |
| 2022-06-30 | -$22.66M | -$903.00 |
| 2021-06-30 | -$38.30M | -$2,800.00 |
| 2020-06-30 | -$9.13M | -$1,522.50 |
| 2019-06-30 | -$8.05M | $5,530.00 |
| 2018-06-30 | $11.14M | $9,485.00 |
Margins and returns by year
| Period end | Return on equity | Return on capital |
|---|---|---|
| 2025-12-31 | -143.57% | -136.03%* |
| 2024-12-31 | -148.57% | -118.57%* |
| 2024-06-30 | -221.45% | -221.45%* |
| 2022-06-30 | -192.12% | -192.12%* |
| 2018-06-30 | 204.93% | 204.89%* |
* Estimated EBIT: pre-tax income + net interest. This company reports no operating income line.
Cash and debt by year
| Period end | Cash | Debt |
|---|---|---|
| 2025-12-31 | $3.62M | - |
| 2024-12-31 | $12.66M | - |
| 2024-06-30 | $4.91M | - |
| 2023-12-31 | $3.67M | $2.32M |
| 2023-06-30 | $1.53M | - |
| 2022-06-30 | $11.78M | - |
| 2021-06-30 | $10.54M | - |
| 2020-06-30 | $2.39M | - |
| 2019-06-30 | $3.72M | - |
| 2018-06-30 | $5.97M | $1.12K |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|---|---|
| 2025-12-31 | -$27.71M | $6.42M |
| 2024-12-31 | -$14.79M | $1.96M |
| 2024-06-30 | -$7.18M | $607.00K |
| 2023-12-31 | -$12.03M | $478.89K |
| 2023-06-30 | -$11.87M | $1.49M |
| 2022-06-30 | -$20.39M | $2.25M |
| 2021-06-30 | -$18.86M | $5.28M |
| 2020-06-30 | -$7.93M | $495.00K |
| 2019-06-30 | -$6.33M | $426.03K |
| 2018-06-30 | -$9.85M | $495.93K |
Investor relations
Next earnings report
- Next confirmed report
- Nov 13, 2026
- Consensus EPS estimate
- $-0.14
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|---|---|
| 2026-08-14 | Jun 2026 | -$0.15 |
| 2026-05-15 | Mar 2026 | -$0.11 |
| 2026-03-31 | Dec 2025 | -$0.14 |
| 2025-11-14 | Sep 2025 | -$0.15 |
| 2025-08-14 | Jun 2025 | -$0.14 |
| 2025-05-15 | Mar 2025 | -$0.13 |
| 2024-11-14 | Sep 2024 | - |
| 2024-05-14 | Mar 2024 | - |
Filings and sources
- Company website
- tuhurabio.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Insmed Inc (INSM) · Bio-Techne Corp (TECH) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR)
Understanding these figures
Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades